The chemistry is right for SB

The UK's second biggest drug company looks attractive, with a healthy stream of new products

INVESTORS who are into drugs have had plenty of trips and some interesting highs for their money of late, as the pharmaceuticals sector outperforms the overall stock market.

Takeover rumours have sent Zeneca zooming, a bid on the table has injected new life into Fisons, and Glaxo Wellcome has seen its shares spark after encouraging reports on the effectiveness of its Aids drug AZT.

SmithKline Beecham has also joined in the party. Its "A" shares, which stood at 460p at the beginning of the year, have gained new momentum over the past few months.

Last week, they hit record highs ahead of the group's key briefing meetings with UK and US analysts, focusing on the group's all-important portfolio of drugs under development.

SB announced it would be seeking approval for around 50 products over the next three years. Among these are 13 new drugs, as well as a raft of variations on existing products.

The most significant of the new products include its Coreg/ Kredex drug for congestive heart failure, Hycamtin for ovarian cancer, Ropinirole for Parkinson's disease, and the asthma treatment Pranlukast.

A healthy flow of new drugs and potential blockbuster products is the life blood of all drug companies, not least SB, whose previous big earner, the ulcer drug Tagamet, came off patent last year. Analysts were impressed, and strong buying on both sides of the Atlantic pushed its "A" shares even higher.

In the UK, SB plays second fiddle to the new Glaxo Wellcome combine, and worldwide it is the sixth largest group. On top of that, last year's flurry of acquisitions helped propel it to number three in the fast-growing consumer healthcare market.

SB also hits the top of the league table for chief executive pay. Former boss Bob Bauman was one of the first to break the pounds lm-a-year barrier, and the current head, Danish-born former Wimbledon semi-finalist Jan Leschley, took home a handy pounds 2.4m package last year.

However, the pace of change since Mr Leschley took over has sidelined the debate over pay. SB's pounds 5bn acquisition bonanza last year added US drug distributor DPS, as well as Sterling Health, a leader in over-the- counter medicines. SB subsequently sold Sterling's US brands to Bayer of Germany, and also disposed of its own animal health arm as part of the group shake-up.

Pharmaceuticals make up around three-quarters of trading profits at SB, while 16 per cent come from its consumer health division, spanning brands such as Panadol, Night Nurse, Macleans toothpaste, Ribena, and Lucozade.

The acquisitions put what Mr Leschley described as the main components in place for future growth. While analysts admire the strategy, reinforcing SB's position in the consolidating international drugs market, some query whether pounds l.4bn was too generous a price for the drug distributor DPS.

The restructuring has left SB with hefty borrowings to finance - net debt is just over pounds 2bn, putting gearing at the half-year at around 100 per cent. A further pounds 580m has been earmarked for restructuring costs over the next three years.

After his racing start as head of SB, Mr Leschley is having to meet high expectations, as analysts look for strong earnings growth and the full benefits of the recent acquisitions to kick in.

SB at least has two significant advantages over rival Glaxo Wellcome. First, it is six years into its big merger, after its link-up with Beecham in 1989, while Glaxo is just beginning to get to grips with Wellcome.

Secondly, SB has already absorbed the impact of Tagamet losing its patent protection, whereas for Glaxo, the end of the line for its key product Zantac looms in 1997.

SB confounded gloomy predictions with its first-half figures in July. Impressive growth from new drugs such as the anti-depressant treatment Seroxat and an anti-nausea drug, Kyril, helped offset the sharp fall in Tagamet sales.

Trading remains tough for all the drugs companies. With the emphasis in the US and UK on cheaper health care, the name of the game, Mr Leschley says, is volume rather than margin growth, topped up by increased efficiency and cost-cutting to drive future earnings growth.

Despite the caution, analysts remain bullish on overall market prospects, a view that has underpinned the sector's growth this year.

Analysts are looking for profits at SB for the year to December to top pounds l.33bn against pounds l.27bn last time, with the group on a multiple around 18, which looks high but is not too demanding given market forecasts.

While the shares may see profit-taking in the short term, SB's promise of strong growth from a broad range of drugs in lucrative markets should ensure they retain their appeal.

SmithKline Beecham

Share price 640p Prospective yield 2.7% Prospective price-earnings ratio 18.7 Dividend cover 2.46 1993 1994 1995*

Sales pounds 6.16bn pounds 6.49bn pounds 6.94bn Pre-tax profits pounds 1.16bn pounds 1.27bn pounds 1.35bn Earnings per share 29.1p 32.3p 34.2p Dividend per share 10.9p 12.9p 13.9p

* Nikko Europe forecast

Start your day with The Independent, sign up for daily news emails
election 2015The 10 best quotes of the campaign
A caravan being used as a polling station in Ford near Salisbury, during the 2010 election
election 2015The Independent's guide to get you through polling day
David Blunkett joins the Labour candidate for Redcar Anna Turley on a campaigning visit last month
voicesWhat I learnt from my years in government, by the former Home Secretary David Blunkett
ebooksA celebration of British elections
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Editor-in-chief - Financial Services - City, London

£60000 - £70000 per annum + benefits : Ashdown Group: A highly successful, glo...

Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Guru Careers: Management Accountant

£27 - 35k + Bonus + Benefits: Guru Careers: A Management Accountant is needed ...

Guru Careers: Project Manager / Business Analyst

£40-50k + Benefits.: Guru Careers: A Project Manager / Business Analyst is nee...

Day In a Page

General Election 2015: ‘We will not sit down with Nicola Sturgeon’, says Ed Balls

'We will not sit down with Nicola Sturgeon'

In an exclusive interview, Ed Balls says he won't negotiate his first Budget with SNP MPs - even if Labour need their votes to secure its passage
VE Day 70th anniversary: How ordinary Britons celebrated the end of war in Europe

How ordinary Britons celebrated VE Day

Our perception of VE Day usually involves crowds of giddy Britons casting off the shackles of war with gay abandon. The truth was more nuanced
They came in with William Caxton's printing press, but typefaces still matter in the digital age

Typefaces still matter in the digital age

A new typeface once took years to create, now thousands are available at the click of a drop-down menu. So why do most of us still rely on the old classics, asks Meg Carter?
Discovery of 'missing link' between the two main life-forms on Earth could explain evolution of animals, say scientists

'Missing link' between Earth's two life-forms found

New microbial species tells us something about our dark past, say scientists
The Pan Am Experience is a 'flight' back to the 1970s that never takes off - at least, not literally

Pan Am Experience: A 'flight' back to the 70s

Tim Walker checks in and checks out a four-hour journey with a difference
Humans aren't alone in indulging in politics - it's everywhere in the animal world

Humans aren't alone in indulging in politics

Voting, mutual back-scratching, coups and charismatic leaders - it's everywhere in the animal world
Crisp sales are in decline - but this tasty trivia might tempt back the turncoats

Crisp sales are in decline

As a nation we're filling up on popcorn and pitta chips and forsaking their potato-based predecessors
Ronald McDonald the muse? Why Banksy, Ron English and Keith Coventry are lovin' Maccy D's

Ronald McDonald the muse

A new wave of artists is taking inspiration from the fast food chain
13 best picnic blankets

13 best picnic blankets

Dine al fresco without the grass stains and damp bottoms with something from our pick of picnic rugs
Barcelona 3 Bayern Munich 0 player ratings: Lionel Messi scores twice - but does he score highest in our ratings?

Barcelona vs Bayern Munich player ratings

Lionel Messi scores twice - but does he score highest in our ratings?
Martin Guptill: Explosive New Zealand batsman who sets the range for Kiwis' big guns

Explosive batsman who sets the range for Kiwis' big guns

Martin Guptill has smashed early runs for Derbyshire and tells Richard Edwards to expect more from the 'freakish' Brendon McCullum and his buoyant team during their tour of England
General Election 2015: Ed Miliband's unlikely journey from hapless geek to heart-throb

Miliband's unlikely journey from hapless geek to heart-throb

He was meant to be Labour's biggest handicap - but has become almost an asset
General Election 2015: A guide to the smaller parties, from the the National Health Action Party to the Church of the Militant Elvis Party

On the margins

From Militant Elvis to Women's Equality: a guide to the underdogs standing in the election
Amr Darrag: Ex-Muslim Brotherhood minister in exile still believes Egypt's military regime can be replaced with 'moderate' Islamic rule

'This is the battle of young Egypt for the future of our country'

Ex-Muslim Brotherhood minister Amr Darrag still believes the opposition can rid Egypt of its military regime and replace it with 'moderate' Islamic rule, he tells Robert Fisk
Why patients must rely less on doctors: Improving our own health is the 'blockbuster drug of the century'

Why patients must rely less on doctors

Improving our own health is the 'blockbuster drug of the century'